-
Mashup Score: 0Giant cell arteritis can occur in people of colour - 1 year(s) ago
Giant cell arteritis is the most common form of systemic vasculitis in individuals aged 50 years or more and is considered a medical emergency. Urgent diagnosis and initiation of treatment are crucial to prevent the serious potential sequalae of permanent visual loss and vascular complications. Giant cell arteritis can present with non-specific symptoms and although fast-track investigative…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Alcohol and health: all, none, or somewhere in-between? - 1 year(s) ago
No level of alcohol consumption is safe when it comes to human health, according to a WHO statement released in January, 2023. The data behind this dire warning come from a 2021 study that estimated the number of incident cancers attributable to alcohol consumption in the EU in 2017—light to moderate drinking (1–2 drinks per day) was responsible for 23 300 new cases of cancer. New Canadian…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Alcohol and health: all, none, or somewhere in-between? Read our April editorial https://t.co/3f8u6Pmtod https://t.co/gNcmemI9WK
-
-
Mashup Score: 0
The association of female sex with certain rheumatic symptoms and diseases is now indisputable. Some of the most striking examples of this association occur in individuals with musculoskeletal pain and osteoarthritis, in whom sex-dependent changes in incidence and prevalence of disease are seen throughout the lifecourse. Joint and muscle pain are some of the most common symptoms of menopause, and…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW REVIEW—Malvika Gulati and colleagues discuss the influence of #sex hormones on musculoskeletal #pain and #osteoarthritis https://t.co/Mxjn6UBquY @malvikagulati_1 https://t.co/uzZ2CWjaDU
-
-
Mashup Score: 0
The MIRACLE study showed that the efficacy of adalimumab combined with reduced methotrexate dose was not inferior to that with the maximum tolerated methotrexate dose, with a tendency to a better safety profile.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—What is the optimal dose of #methotrexate to administer with a TNF inhibitor? The MIRACLE trial shows that adalimumab + reduced-dose methotrexate is non-inferior to adalimumab + maximal-dose methotrexate in patients with #rheumatoidarthritis https://t.co/RofdRqNbvG https://t.co/LRdzvVKQae
-
-
Mashup Score: 0Methotrexate in rheumatoid arthritis—another brick in the wall - 1 year(s) ago
Methotrexate has remained the mainstay in rheumatoid arthritis therapy, and the most recent EULAR recommendations emphasise methotrexate as part of the first-line treatment strategy unless contraindicated or not tolerated.1 This recommendation is based on more than 35 years of experience with methotrexate, its well characterised clinical efficacy, inhibition of radiographic progression,…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Methotrexate in rheumatoid arthritis—another brick in the wall Linked Comment by Andrea Rubbert-Roth https://t.co/neSavVI0xJ https://t.co/giA0qE3sIj
-
-
Mashup Score: 2Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus - 1 year(s) ago
Systemic lupus erythematosus is a complex, systemic autoimmune disease characterised by immune dysregulation. Pathogenesis is multifactorial, contributing to clinical heterogeneity and posing challenges for diagnosis and treatment. Although strides in treatment options have been made in the past 15 years, with the US Food and Drug Administration approval of belimumab in 2011, there are still many…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
ICYMI in our March issue—Katherine Nay Yaung and colleagues review artificial intelligence and high-dimensional technologies in the theragnosis of systemic #lupus erythematosus #SLE https://t.co/VJ07zfZxUe https://t.co/REn4HzeU1Z
-
-
Mashup Score: 0
A 34-year-old woman, 22 weeks pregnant, attended the National University Hospital, Singapore, reporting asymptomatic hypertension on home blood pressure monitoring.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW CLINICAL PICTURE—Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus https://t.co/cG1m7Hkz4g #SLE https://t.co/5CHjZ606Tu
-
-
Mashup Score: 01-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial - 1 year(s) ago
After a single dose of rituximab (1000 mg), the proportion of patients with polymyalgia rheumatica in glucocorticoid-free remission remained stable at 1 year after infusion, and a glucocorticoid sparing effect was evident. A larger trial including possibility for retreatment is warranted to confirm these results.
Source: The Lancet RheumatologyCategories: Healthcare Professionals, Latest HeadlinesTweet-
BRIDGE-PMR a proof-of-concept trial studied 1 dose of IV RTX in 47 PMR pts - at 1 yr, 52% RTX were in GC-free remission (compared to 21% given PBO). Eight (33%) patients in the placebo group and six (26%) in the rituximab group had adverse events https://t.co/yv8ezFN5BJ https://t.co/7FOOPbEIf3
-
-
Mashup Score: 0Thank you to our contributors and peer reviewers in 2022 - 1 year(s) ago
With the COVID-19 pandemic slowly receding, 2022 felt like a tentative step toward normality. Nonetheless, SARS-CoV-2 continues to challenge populations and health systems globally, and questions and uncertainties remain among patients who are immunocompromised—including many with rheumatic and musculoskeletal diseases. Reflecting these ongoing questions, a third of the research Articles…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
The rigorous work published in our journal is only possible as a result of the dedication and commitment of our peer reviewers. We are extremely grateful to all of The Lancet Rheumatology's 2022 reviewers https://t.co/gWNMwikH9g Full list: https://t.co/tfHUc8yUFn https://t.co/09MifcJGFg
-
-
Mashup Score: 0Prevention of psoriatic arthritis: the next frontier - 1 year(s) ago
Psoriatic arthritis is a heterogeneous inflammatory musculoskeletal condition that affects up to a fourth of patients with psoriasis over their lifetime and is notoriously challenging to identify and manage.1 Approximately 30% of patients with psoriatic arthritis reach remission after treatment with targeted biological therapies, and average time on therapy is only 1 year.1 Given these…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
@docrheumatic @EBRheum @rheum_cat Prevention of psoriatic arthritis: the next frontier Linked Comment by @AlexisOgdie & Jose U Scher https://t.co/OobWd92CZL https://t.co/bHexch0yLW
-
"Race should not influence diagnostic decision making in giant cell arteritis" NEW COMMENT—#GCA can occur in people of colour https://t.co/JkK54GAHC9 @GillTiara @EBRheum @SattuiSEMD @DrSHamdulay @RichardPAConway @drdavidliew @Amansharmapgi @Sarah_L_Mackie @DrPujaMehta1 https://t.co/OmlVXkfP9c